Researchers propose a new model for Alzheimer's disease (AD2) that considers the neurodegenerative disease as an autoimmune disease that attacks the brain. Considering Alzheimer's as an autoimmune disorder could spark a new line of therapies to treat the disease.
DDT exposure causes sodium channels to remain open, leading to increased neural firing and an increased release of amyloid beta peptide. Blocking the channels with tetrodotoxin reduces the toxic amyloid protein by increasing the production of the amyloid precursor protein.
A new collection of articles explores mapping brain overexcitability that underpins the dysregulation of vigilance, sleep-wake cycles, and validating effective biomarkers for Alzheimer's disease.
Recent scandals in Alzheimer's research and problems with medications designed to help those with Alzheimer's but failing to deliver sufficient results have researchers questioning the overwhelming focus on amyloid-beta in Alzheimer's research.
Study reveals how somatostatin and copper affect amyloid beta in Alzheimer’s disease pathology.
Whole blood exchange effectively decreases the formation of amyloid beta in the brains of mouse models of Alzheimer's disease.
Study reveals the role of the urea cycle in the brain and explores the dual nature of astrocytes in the brains of those with Alzheimer's pathology.
A smaller version of the amyloid-beta protein, AB 1-40, builds up on the wall of small arteries and reduces blood flow to the brain, a new study reports.
Rapamycin, a drug approved for the treatment of cancer and transplant patients increases amyloid-beta protein plaques in the brains of mice.
The heat produced by amyloid-beta aggregation may cause other, healthy amyloid-beta to aggregate, causing more and more aggregates to form. However, with the addition of a novel drug compound, amyloid-beta aggregation can be stopped and the cell temperature lowered.
A new mouse study reveals a breakdown in the process that clears brain cells of waste products precedes the buildup of amyloid plaques associated with Alzheimer's disease.
A combination of patient-reported subjective cognitive impairment and measurable clinical symptoms, such as amyloid-beta accumulation in the cerebrospinal fluid, may help in the early diagnosis of Alzheimer's disease.